Vor Bio is working on a new platform for treating and curing blood cancers.
Combining expertise in Hematopoietic Stem Cell (HSC) biology, genome engineering, and the development of Chimeric Antigen Receptor T (CAR-T) cell therapies, we will realize our vision of a cure only with the help of first-class external partners.
Acute Myeloid Leukemia (AML) is a blood cancer that still lacks highly effective treatment options. While many patients receive Hematopoietic Cell Transplants (HCTs), around 40% will relapse following their transplant with two-year survival rates of less than 20%.
Now, working with partners and across disciplines, Vor Bio is developing a new approach. Based upon a deep understanding of HSC biology and using recent advances in genome engineering, we are editing HSCs to protect them from the damaging effects of targeted therapies post-transplant. This potentially allows treatment with powerful targeted therapies such as CAR-Ts soon after transplant. Preclinical data shows that our approach can protect healthy cells without compromising blood cell populations or function. Vor Bio is now working with top transplant centers to recruit patients into a clinical trial evaluating this approach.